To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
6 Current news about the topic fibromyalgiarss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
Study points to possible trigger of symptoms
Most people aren’t worn out by simple daily tasks requiring little exertion. But those with chronic fatigue syndrome might be exhausted by a walk across the room. A study by University of Florida Health researchers published recently in the Journal of Pain Research provides a possible explanation ...
Study suggests fibromyalgia is a spectrum disorder
Researchers have determined that fibromyalgia prevalence is 2.1% of the general population in Germany. Results suggest that fibromyalgia is a spectrum disorder rather than a categorical illness. Additionally, a number of fibromyalgia cases in the general population satisfy proposed criteria for ...
Rubbing or massaging is often an instinctive response to pain. Now researchers have found that another kind of touch, vibration, can also help reduce certain types of pain by more than 40 percent. The researchers are encouraged by the prospect that vibration therapies could bring pill-free pain ...
Jazz Pharmaceuticals, Inc. and UCB announced positive preliminary top-line results from the second of two Phase III clinical trials of sodium oxybate (JZP-6) for the treatment of fibromyalgia. Confirming the positive results from the first Phase III study, this international, placebo-controlled ...
Preliminary Top Line Results of Phase III Trial Show Significant Decreases in Pain and Fatigue and Improved Daily Function in Fibromyalgia Patients
Jazz Pharmaceuticals, Inc. and UCB announced positive preliminary top-line results from the first of two Phase III clinical trials of sodium oxybate (JZP-6) for the treatment of fibromyalgia. The randomized, double-blind, placebo-controlled study achieved its key endpoints, demonstrating that ...
Sosei Co. Ltd announced that its wholly-owned subsidiary Arakis Ltd, has successfully completed Phase I single and multidose studies of AD 337, a novel enantiomer of an approved centrally acting non-opioid analgesic, which is under investigation for the treatment of fibromyalgia syndrome. AD 337 ...